Current Neuro-Oncology
Volume
27 Number 21
31 July 2025
Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 21, 31 July
Astrocytoma, anaplastic; Astrocytoma, NOS; Glioblastoma, NOS; Oligodendroglioma, anaplastic; Oligodendroglioma, NOS
Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ,
Eisele Y, Beumer J, Parise R, Urban J, Rose A, Sellitto L, Singh
K, Doerfler R, Dadey RE, Kim C, Rhee JC, Davar D, Villaruz LC,
Burgess M, Drappatz J, Mantica M, Goodman AE, Wang H, Singhi AD,
Luke JJ, Zandberg DP, Bao R.
Clinical
and translational study of ivosidenib plus nivolumab in advanced
solid tumors harboring IDH1 mutations.
medRxiv
[Preprint]. 2025 Jul 21:2025.07.19.25331848. doi:
10.1101/2025.07.19.25331848. PMID:
40778139. Interventional study. ˍ
ClinicalTrials.gov
ID: NCT04056910.
Blobner J, Ruf V, Weller J, Teske N, Forbrig R, Thon N, Albert NL,
von Baumgarten L, Schoenecker S, Tonn JC, Ringel F, Harter PN,
Karschnia P.
Clinical and
neuropathological criteria for distinguishing between IDH-mutant
astrocytomas of WHO grade 2 and 3.
J
Neurooncol. 2025 Jul 23. doi:
10.1007/s11060-025-05173-z. PMID:
40702387. Observational study. ˍ
Oster C, Matyar A, Schmidt T, Hummel T, Hattingen E, Jokisch M,
Jokisch D, Grieger J, Cappello G, Kizina K, Lazaridis L,
Ahmadipour Y, Rauschenbach L, Stuschke M, Pöttgen C, Guberina
N, Tertel T, Giebel B, Dreizner GL, Barbato F, Skoda EM, Scheffler
B, Müther M, Herrmann K, Kleinschnitz C, Sure U, Deuschl C,
Glas M, Kebir S.
Decoding glioblastoma
survival: unraveling the prognostic potential of olfactory
function in a prospective observational study.
Neurol
Res Pract. 2025 Jul 24;7(1):51. doi:
10.1186/s42466-025-00410-2. PMID:
40708059. Interventional study
protocol.
ˍ
ClinicalTrials.gov
ID: NCT06954636.
Tang LY, Botros D, Kim AA, Khalafallah AM, Dux H, Fox K, Hussain
N, Mao Y, Pellegrino R, Sharma P, Lucas CG, Ahmed AK, Jackson CM,
Gallia G, Bettegowda C, Weingart J, Brem H, Mukherjee D.
Impact
of peri-tumoral resection on survival in primary glioblastoma.
Cancer.
2025 Jul 24;131(15):e70016. doi:
10.1002/cncr.70016. PMID:
40704606. Observational study˰
ˍ
Youssef M, Larson A, Udhane V, Schilter KF, Nie Q, Reddi HV.
Analysis of cerebrospinal fluid
tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma
in an adult.
J
Liq Biopsy. 2025 Jul 25;9:100318. doi:
10.1016/j.jlb.2025.100318. PMID:
40792228. Case report. ˍ
Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk MEG, Hoving
EW, Wesseling P, Visser O, van Vuurden DG, Gatta G, Karim-Kos HE;
EUROCARE working group.
Long-term
survival and cure
fraction estimates for paediatric
central nervous system tumours in 31 European countries
(EUROCARE-6): a population-based study.
Lancet Oncol.
2025 Jul 28;26(8):1091-1099. doi:
10.1016/S1470-2045(25)00297-9. PMID:
40744027. Observational study˰
ˍ
McCabe M, Rossi S, Cerza F, Massimino M, Gianno F, Spycher BD,
Marcos-Gragera R, Bennett D, Lasalvia P, Didonè F, El
Karoui NJ, Ragusa R, Mayer-da-Silva A, Mousavi SM, Trama A;
EUROCARE-6 WG.
Survival of European
adolescents and young adults diagnosed with central nervous system
tumours and comparison with younger and older age groups:
EUROCARE-6 results.
Eur
J Cancer. 2025 Jul 28;227:115661. doi:
10.1016/j.ejca.2025.115661. PMID:
40782412. Observational study. ˍ
Qian X, Ning W, Yang J, Dunmall LC, Pandha HS, Shang G, Guo Y,
Zhang D, Qu Y, Wang H, Gu C, Zhang M, Wang Y, Wang S, Zhang H.
The oncolytic adenovirus Ad-TD-nsIL12
in primary or progressive pediatric IDH wild-type diffuse
intrinsic pontine glioma results of two phase I clinical trials.
Nat
Commun. 2025 Jul 28;16(1):6934. doi:
10.1038/s41467-025-62260-5. PMID:
40721414. Interventional study.
ˍ
ClinicalTrials.gov
ID: NCT05717712; ClinicalTrials.gov
ID: NCT05717699.
Faison SL, Batonga J, Arumugham T, Bartkus A, Morrison ME, Mullin
MJ, Tippin T, Naderer O.
Effect of
Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics.
Drugs
R D. 2025 Jul 30. doi:
10.1007/s40268-025-00520-x. PMID:
40742663. Interventional study.
ˍ
ANZctr.org.au
ID: ACTRN12622000405718.